drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Allogeneic 4SCAR CAR T cells engineered to target CD38 on myeloma cells, delivering CD3ζ-based activation with co-stimulation to induce selective cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor T cells engineered to express a CD38-specific 4SCAR (CAR with CD3ζ activation and co-stimulatory domains) bind CD38 on myeloma cells, triggering T‑cell activation, cytokine release, proliferation, and targeted cytotoxic killing of malignant plasma cells as an off‑the‑shelf cellular immunotherapy.
drug_name
Universal allogeneic anti-CD38 4SCAR T cells
nct_id_drug_ref
NCT06006741